Valneva’s Forward-Looking Statements
This press release includes certain forward-looking statements related to Valneva’s business, adding regarding the progress, timing and finishing touch of research, progression and clinical trials for the candidate products, ability to manufacture, location of product candidate market, the ability to protect high-level assets and operate the business without infringing the high-level asset rights of others, long-term functionality estimates and anticipated operating loss estimates, long-term revenue, needs capital and additional financing needs. Furthermore, even if the actual effects or progression of Valneva are consistent with the forward-looking statements contained in this press release, those effects or progressions of Valneva may not be indicative of its long term. In some cases, you can identify forward-looking statements by words such as “possibly”, “should”, “possibly”, “expect”, “anticipate”, “believe”, “intend”, “believe”. “,” objectives “,” goals “or similar words. These forward-looking statements are based on a giant component of Valneva’s existing expectations as of the date of this press release and are subject to a number of known and unknown dangers and uncertainties and other points that would possibly cause effects, actual functionality or achievement, in addition to the long-term effects, functionalities or achievements expressed or implied through those forward-looking statements. In components, Valneva’s expectations may also be affected, among other things , through insecurities similar to vaccine progression and manufacture, unforeseen effects of clinical trials, unforeseen regulatory movements or delays, festivals in general, fluctuations in financial policy, the effect of the European credit crisis and the ability to download or maintain patents or other highly owned assets Despite these dangers and insecurities, no There may be assurance that the forward-looking statements made during this presentation will be true. Valneva provides the data in those documents of this press release and disclaims any legal purpose or responsibility to publicly update or revise any forward-looking statement, whether as a result of new data, long-term occasions, or otherwise.
1Valneva confirms its participation in the UK government’s COVID-19 vaccine reaction programme
Attachment file